16-Week Data From SALWEEN Fill the Gap for Patients With PCV

By week 16, average BCVA gain was slightly more than seven letters and CST was just over 400 μm.

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCIMichael A. Singer, MD

Retinal Physician March 17, 2025

1

The SALWEEN study investigates the efficacy and safety of faricimab in patients with polypoidal choroidal vasculopathy (PCV).
2

By week 16, patients in the SALWEEN study experienced an average BCVA gain of over seven letters and a reduction in CST to just over 400 μm.
3

The polyp closure rate at week 16 was 51%, indicating a robust response to treatment compared to previous monotherapy studies.
4

More than 80% of eyes showed no active polyps, suggesting effective disease control in the SALWEEN trial.
5

The study's ongoing design allows for flexible retreatment intervals based on disease activity, aiming to optimize patient outcomes.

1